Navigation Links
Sumitomo to Act As Advisor to ProMetic for Japanese Market
Date:4/30/2009

MONTREAL and NEW YORK, April 30 /PRNewswire/ -- ProMetic Life Sciences Inc. (TSX: PLI) ("ProMetic") and Sumitomo Corporation of America ("SCOA") announces that it has retained the services of SCOA and Summit Pharmaceuticals International ("SPI"), both wholly owned subsidiaries of Sumitomo Corporation ("Sumitomo") to advise ProMetic in its business development activities relating to PBI-1402 for the Japanese market.

In the course of ProMetic's partnering activities several Japanese companies have signaled their interest in PBI-1402. Consequently, ProMetic has retained the services of Sumitomo to capitalize on this asset. Sumitomo's reach and experience in various commercial fields will facilitate the leveraging of PBI-1402's value for this market.

"Sumitomo is pleased to advise and support ProMetic's activities that aim to increase PBI-1402's reach into the high-return environment of the Japanese market," said Mr. Yasunori Ishibashi, Senior Director of SCOA's Life Science Unit. "There is increasing demand in Japan for therapeutic drugs such as PBI-1402 that would treat anemia problems associated with cancer treatment and kidney disease. Our agreement with ProMetic allows them to access the global network and business development services of Sumitomo, while at the same time giving us an option for further investment down the road," states Mr. Ishibashi.

According to Mr. Masahiro Sasaki, President of SPI, "We believe that PBI-1402, with its novel mechanism of action, will become a promising drug for the treatment of anemia associated with cancer and kidney diseases. The need for such indication is high in Japan as well. We look forward to assisting ProMetic in choosing an appropriate partner for this compound, making the best of the abundant experiences and network of SPI."

About ProMetic Life Sciences Inc.

ProMetic Life Sciences Inc. ("ProMetic") ('/>"/>

SOURCE Sumitomo Corporation of America
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine news :

1. Sumitomo Corporation Appoints New Chairman to U.S. Animal Healthcare Company Summit VetPharm, LLC
2. Malaria No More and Sumitomo Chemical Help Protect 1.4 Million Kids from Malaria
3. Conference Call Advisory - NUCRYST Pharmaceuticals Corp. Conference Call to Discuss 2009 First Quarter Results
4. Global Advisor and Speaker Explains Middle East Investors, Politics, Culture
5. Christine Cassel, MD Appointed to President Obamas Council of Advisors on Science and Technology
6. Media Advisory: PHR Experts Available to Comment on Torture
7. FDA Advisory Committee Recommendation on SEROQUEL XR Supplemental New Drug Applications
8. Obama Nominates Former Advisory Board Company Executive
9. Leading Independent Proxy Advisory Firm Supports Specialty Underwriters Alliance, Inc. in Its Proxy Contest Against Hallmark Financial Services, Inc.
10. 2010 Dietary Guidelines Advisory Committee Meeting to Be Webcast April 29th and 30th
11. TorreyPines Therapeutics, Inc. Hires Advisor to Evaluate Strategic Alternatives

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/3/2009)..., , SOUTHBRIDGE, Mass., Dec. 3 /PRNewswire/... approval to treat its first patients, Harrington ...t seeing patients immediately," said Diane Becquar..., The approval was granted today by the Massachu...ty and quality review of the facility. ,, The ...
(Date:12/3/2009)..., , BEIJING, Dec. 3 /PRNewswire-Asia/...enefits, ginger, one of the most important ingredi...in China during this flu season. , The ti... supply shortages,effecting upward price pressure...potential repeat of the current demand hysteria ov...
(Date:12/3/2009)..., , SILVER SPRING, Md., Dec. 3 /PRNewsw...g a health care system that ensures affordable, qu...on urges all Americans to contact their representa...h care reform. ,, See video from ANA at: http:...dvocating for a health care system that focuses on...
(Date:12/3/2009)...Roles of aggressor, victim often play out at schoo...c. 3 (HealthDay News) -- School bullies are also l... according to an Italian study that included 195 c...rticipants -- all with a sibling no more than four...ether they bullied or were bullied at school or at...
(Date:12/3/2009)...Finding could aid in eventual development of scree...DAY, Dec. 3 (HealthDay News) -- New research point...amin D and heart disease. , People with high bl...itamin D activation in the body were found to be t...e congestive heart failure, the study found. , ...
Breaking Medicine News(10 mins):Health News:Cancer Center at Harrington to Begin Seeing Patients 2Health News:Cancer Center at Harrington to Begin Seeing Patients 3Health News:Ginger Prices Could Skyrocket on H1N1 Fears 2Health News:VIDEO from Medialink and the American Nurses Association (ANA): American Nurses Association Urges All Americans to Take Part in Health Care Reform Debate 2Health News:Bullies May Intimidate Siblings, Too 2Health News:Vitamin D May Be Tied to Heart Disease Via Genes 2
...anizations are turning to Amalga to connect hospit...h centers., REDMOND, Wash., June 24 To improve t...to medically underserved,D.C. residents, the Distr... hospitals and six community-based health,centers ...
...COUVER, June 24 /PRNewswire-FirstCall/ - Beeston E...BB: BESE) announces that it completed,drilling on ... from,Candorado Operating Company Ltd. (TSX Ventur... copper-gold deposits., The Company is carrying o...
...New evidence-based guidelines address the preventi...ulations and reinforce recommendations related to ... as a supplement in the June issue of CHEST , the...ice Guidelines, Eighth Edition was developed by an...
...cuity,s Release of PriceAdvisor Combats Ineffectiv...action & Improve Revenue Projection and Recovery ...HILLS, Ill. and DUBLIN, Ireland, June 24 /PRNewswi...ology ("Peer,Reviewed by HFMA") and services, toda...
...tery shoppers allow providers to compare real expe...pectations., DALLAS, June 24 Mystery shopping go... why patients leave -- sometimes without,ever meet...come patients because they dismiss a healthcare or...
...3M Health Care today announced the launch of the 3...cal mask to meet the needs of clinicians seeking a...urgical mask incorporates proprietary filtration m... design, the 3M Filtron 1900 surgical mask provide...
Other Medicine News:Health News:District of Columbia Primary Care Association Selects Microsoft Amalga to Improve Patient Care for the Underserved 2Health News:District of Columbia Primary Care Association Selects Microsoft Amalga to Improve Patient Care for the Underserved 3Health News:Beeston completes drilling on Bluff Lake property, 100 Mile House 2Health News:New blood clot guidelines for pregnant women 2Health News:New blood clot guidelines for pregnant women 3Health News:New blood clot guidelines for pregnant women 4Health News:Concuity Announces the Availability of PriceAdvisor 2Health News:Concuity Announces the Availability of PriceAdvisor 3Health News:Concuity Announces the Availability of PriceAdvisor 4Health News:New White Paper from The Beryl Institute: 'Mystery Shopping the Patient Experience' 2Health News:3M Health Care launches new high-performance surgical mask 2
(Date:12/3/2009)... Dec. 3 ParagonRx, a Delaware-base...gement and optimal medication use, will host a fre... guidance on REMS - Risk Evaluation Mitigation Str...ecycle management. Dr. Gary Slatko, chief medical...sk management programs, will lead the one-hour pro...
(Date:12/3/2009)... Cardium Therapeutics (NY...ned subsidiary, Tissue Repair Company, submitted a.... Food and Drug Administration (FDA) seeking marke...didate based on positive data from the Company,s r... Today,s submission with the FDA covers Excellagen...
(Date:12/3/2009)...lif., Dec. 3 Each year, ... United States (U.S.) and Europe participate in th...ry experience under renowned faculty members at th...holars - past, present and future - will have excl...y at www.amgenscholars.com . ,, "The new Web ...
Breaking Medicine Technology:Cardium Files FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Topical Gel and ExcellagenFX(TM) Flowable Collagen Protein-Based Matrix for Diabetic, Pressure and Venous Ulcers and Other Dermal Wounds 2Cardium Files FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Topical Gel and ExcellagenFX(TM) Flowable Collagen Protein-Based Matrix for Diabetic, Pressure and Venous Ulcers and Other Dermal Wounds 3Cardium Files FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Topical Gel and ExcellagenFX(TM) Flowable Collagen Protein-Based Matrix for Diabetic, Pressure and Venous Ulcers and Other Dermal Wounds 4Cardium Files FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Topical Gel and ExcellagenFX(TM) Flowable Collagen Protein-Based Matrix for Diabetic, Pressure and Venous Ulcers and Other Dermal Wounds 5New Amgen Scholars Web site Launches to Build a Global Network for Future Scientists 2New Amgen Scholars Web site Launches to Build a Global Network for Future Scientists 3Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014 3A Policy environment market structure competitive landscape growth oppo 5528 1Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014 3A Policy environment market structure competitive landscape growth oppo 5528 2Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014 3A Policy environment market structure competitive landscape growth oppo 5528 3Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014 3A Policy environment market structure competitive landscape growth oppo 5528 4Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014 3A Policy environment market structure competitive landscape growth oppo 5528 5Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014 3A Policy environment market structure competitive landscape growth oppo 5528 6Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014 3A Policy environment market structure competitive landscape growth oppo 5528 7Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014 3A Policy environment market structure competitive landscape growth oppo 5528 8Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014 3A Policy environment market structure competitive landscape growth oppo 5528 9Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014 3A Policy environment market structure competitive landscape growth oppo 5528 10Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014 3A Policy environment market structure competitive landscape growth oppo 5528 11Maternal HIV 1 treatment protects against transmission to newborns 59640 1Maternal HIV 1 treatment protects against transmission to newborns 59640 2University of the Basque Country study on proteins related to Alzheimers 10397 1University of the Basque Country study on proteins related to Alzheimers 10397 2
...LES--(BUSINESS WIRE)--Jun 27, 2007 - CytRx Corpora...gaged in the,development and commercialization of ... from the six-month, open-label extension,of its c... in ALS,volunteers. While the clinical trial was n...e three times daily appeared to be safe,and well-t...
...e Netherlands, June 27, 2007-Organon, the human,he...day that two,out of three Phase III clinical trial...g-acting fertility hormone, have reached,their ran...ew recombinant fertility hormone. It is,the first ...cular,stimulant or SFS) of which, due to its long ...
Other Medicine Technology:CytRx Reports Promising Data from Its Open-Label Extension Clinical,Trial of Arimoclomol in ALS 2CytRx Reports Promising Data from Its Open-Label Extension Clinical,Trial of Arimoclomol in ALS 3CytRx Reports Promising Data from Its Open-Label Extension Clinical,Trial of Arimoclomol in ALS 4CytRx Reports Promising Data from Its Open-Label Extension Clinical,Trial of Arimoclomol in ALS 5Two Phase III clinical trials on corifollitropin alfa (Org 36286),reach randomization target 2Two Phase III clinical trials on corifollitropin alfa (Org 36286),reach randomization target 3
Medium Clip Appliers
Li Brand™ Surgical Hemostat
The 2201
No Scalpel Vasectomy Hemostat
Medicine Products: